Compare REGN & FDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | FDX |
|---|---|---|
| Founded | 1988 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5B | 89.3B |
| IPO Year | 1995 | 1997 |
| Metric | REGN | FDX |
|---|---|---|
| Price | $748.22 | $389.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 21 |
| Target Price | ★ $827.76 | $376.67 |
| AVG Volume (30 Days) | 536.1K | ★ 1.7M |
| Earning Date | 04-29-2026 | 03-19-2026 |
| Dividend Yield | 0.50% | ★ 1.52% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 41.48 | 11.91 |
| Revenue | $5,872,227,000.00 | ★ $65,450,000,000.00 |
| Revenue This Year | $12.03 | $7.46 |
| Revenue Next Year | $10.42 | $4.92 |
| P/E Ratio | ★ $17.99 | $31.90 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $476.49 | $201.10 |
| 52 Week High | $821.11 | $392.86 |
| Indicator | REGN | FDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 66.82 |
| Support Level | $725.92 | $344.44 |
| Resistance Level | $787.20 | $392.86 |
| Average True Range (ATR) | 17.03 | 8.69 |
| MACD | -0.76 | 2.71 |
| Stochastic Oscillator | 27.22 | 99.02 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment—which houses the core package delivery operations—made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.